Xenetic Biosciences (XBIO) Change in Receivables (2011 - 2025)
Xenetic Biosciences' (XBIO) quarterly Change in Receivables came in at -$780067.0 in Q4 2025, down 433.55% YoY from $233866.0 in Q4 2024, and down 309.41% on a QoQ basis from $372507.0 in Q3 2025.
Xenetic Biosciences (XBIO) Change in Receivables (2011 - 2025) Analysis & Trends
Xenetic Biosciences (XBIO) has 15 years of Change in Receivables data on file, last reported at -$780067.0 in Q4 2025.
- Quarterly Change in Receivables fell 433.55% year-over-year to -$780067.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$255660.0 (down 40.57% YoY) and the FY2025 annual result came in at -$255660.0, down 40.57% from the prior year.
- Change in Receivables fell to -$780067.0 in Q4 2025, from $372507.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $442496.0 in Q2 2023 to a low of -$876734.0 in Q4 2023.
- A 5-year average of -$28603.4 and a median of $86635.5 in 2021 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2021 — Change in Receivables sank 562.4% — and 2023, when it surged 261.48%.
- Tracing XBIO's Change in Receivables over 5 years: stood at -$348491.0 in 2021, then soared by 168.0% to $236991.0 in 2022, then tumbled by 469.94% to -$876734.0 in 2023, then surged by 126.67% to $233866.0 in 2024, then tumbled by 433.55% to -$780067.0 in 2025.
- The last three Change in Receivables figures came in at -$780067.0 (Q4 2025), $372507.0 (Q3 2025), and $260234.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -780,067.00 |
| Dec 31, 2025 | -780,067.00 |
| Sep 30, 2025 | 372,507.00 |
| Sep 30, 2025 | 372,507.00 |
| Jun 30, 2025 | 260,234.00 |
| Jun 30, 2025 | 260,234.00 |
| Mar 31, 2025 | -108,334.00 |
| Mar 31, 2025 | -108,334.00 |
| Dec 31, 2024 | 233,866.00 |
| Dec 31, 2024 | 233,866.00 |
| Sep 30, 2024 | -528,293.00 |
| Sep 30, 2024 | -528,293.00 |
| Jun 30, 2024 | 164,338.00 |
| Jun 30, 2024 | 164,338.00 |
| Mar 31, 2024 | -51,785.00 |
| Mar 31, 2024 | -51,785.00 |
| Dec 31, 2023 | -876,734.00 |
| Dec 31, 2023 | -876,734.00 |
| Sep 30, 2023 | 161,527.00 |
| Sep 30, 2023 | 161,527.00 |